天津医药

天津医药 ›› 2021, Vol. 49 ›› Issue (11): 1228-1232.doi: 10.11958/20210953

• 综述 • 上一篇    

肿瘤坏死因子相关凋亡诱导配体在消化系统肿瘤治疗中的研究进展

李大欢，许良璧，刘雪影，唐山，邓超男   

  1. 1贵州医科大学临床医学院内科教研室（邮编550000），2病理教研室
  • 收稿日期:2021-04-22 修回日期:2021-06-23 出版日期:2021-11-15 发布日期:2021-11-19
  • 基金资助:
    贵州省教育厅青年科技人才成长项目（黔教合KY字【2018】178）；贵州医科大学国家自然科学基金培育项目（19NSP050）

Research progress of TRAIL in the treatment of digestive cancer

LI Da-huan, XU Liang-bi, LIU Xue-ying, TANG Shan, DENG Chao-nan   

  1. 1 Department of Internal Medicine, 2 Department of Pathology, Clinic School, Guizhou Medical University, Guiyang 550000, China
  • Received:2021-04-22 Revised:2021-06-23 Published:2021-11-15 Online:2021-11-19

PDF (PC)

2847

摘要： 肿瘤坏死因子相关凋亡诱导配体（TRAIL）可通过特异性识别肿瘤细胞死亡受体而诱导并启动多种凋亡机制，发挥抑制肿瘤的增殖、浸润、转移的作用，但TRAIL对食管癌、胃癌、大肠癌等消化系统恶性肿瘤治疗并不敏感。TRAIL可通过联合使用某些小分子化合物，或通过调节凋亡相关蛋白的表达等来提高其抑癌的能力，然而其具体作用机制尚不清楚。就肿瘤坏死因子相关凋亡诱导配体在消化系统肿瘤治疗中的研究进展进行综述。

关键词: 消化系统肿瘤, 胃肠肿瘤, 抗药性, 肿瘤, 细胞凋亡, TNF相关凋亡诱导配体

Abstract: Tumour necrosis factor-related apoptosis-inducing ligands (TRAIL) can inhibit tumour proliferation, infiltration and metastasis by specifically recognising tumour cell death receptors and inducing and initiating various apoptotic mechanisms. TRAIL is not sensitive to the treatment of digestive malignancies such as oesophageal, gastric and colorectal cancers. TRAIL can improve its anti-cancer ability by combining some small molecular compounds or by regulating the expression of apoptosis-related proteins. However, its exact mechanism of action is not yet clear. This article reviews the research progress of tumor necrosis factor-related apoptosis-inducing ligand in the treatment of digestive system tumors.

Key words: digestive system neoplasms, gastrointestinal neoplasms, drug resistance, neoplasm, apoptosis, TNF related apoptosis inducing ligand